Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Clarithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | ALB | P02768 | 1/20 | 0.92 |
| ▸ | CNR1 | P21554 | 1/20 | 0.92 |
| ▸ | HTR2A | P28223 | 1/20 | 0.92 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.92 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.92 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clarithromycin SCHEMBL13210325 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL15472892 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL1176361 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL38125 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL24064961 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL17705916 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL23309064 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL14010008 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL23854898 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 | |
| Clarithromycin SCHEMBL12296733 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 65506 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260138957-A1 | UREA-LINKED 2-AMINOIMIDAZOLE DIMER POTENTIATORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4744729-A2 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Deciphera Pharmaceuticals, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4007582-B1 | ANTIBIOTICS IN COMBINATION WITH PHOTODYNAMIC THERAPY FOR USE IN A METHOD OF ENHANCING THE ANTIMICROBIAL ACTION OF SYSTEMICALLY ADMINISTERED ANTIBIOTICS | KOITE HEALTH OY (FI) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-122056853-A | Antibacterial agent based on graphite phase carbon nitride, and preparation method and application thereof | 海南医科大学(海南省医学科学院) | 2026-05-19 | — | — | CN | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| CN-122042848-A | Method for separating and measuring key starting materials and related compounds of clavulanone by HPLC (high Performance liquid chromatography) | 福建大谱生物医药有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-4921839-A | Erythromycin a 11,12-carbonate 9-oxime derivatives | BEECHAM GROUP P.L.C. (GB) | 1990-05-01 | — | — | US | claimed |
| EP-0180415-B1 | A 6-0-methylerythromycin A derivative | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1990-01-31 | — | — | EP | claimed |
| US-4808411-A | ERYTHROMYCIN AND CARBOMER | ABBOTT LABORATORIES (US) | 1989-02-28 | — | — | US | claimed |
| EP-0195960-B1 | METHOD FOR SELECTIVE METHYLATION OF ERYTHROMYCIN A DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1988-12-14 | — | — | EP | claimed |
| EP-0293885-A2 | Antibiotic-polymer compositions | ABBOTT LABORATORIES (US) | 1988-12-07 | — | — | EP | claimed |
| EP-0260938-A2 | Erythromycin A derivatives and method for preparing the same | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1988-03-23 | — | — | EP | claimed |
| EP-0245012-A1 | Method for the preparation of 14-hydroxy-6-0-methyl-erythromycin A | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1987-11-11 | — | — | EP | claimed |
| US-4680386-A | 6-O-methylerythromycin a derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1987-07-14 | — | — | US | claimed |
| EP-0194833-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1986-09-17 | — | — | EP | claimed |
| EP-0180415-A2 | A 6-0-methylerythromycin A derivative | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-05-07 | — | — | EP | claimed |